Flonase (Fluticasone Propionate) Indications
Flonase is FDA-approved for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis in adults and children ≥4 years of age, including nasal congestion, rhinorrhea, sneezing, itchy nose, and itchy/watery eyes. 1
FDA-Approved Indications
Primary Indication: Allergic Rhinitis
- Nasal symptoms: Congestion, runny nose, sneezing, and itchy nose 1
- Ocular symptoms: Itchy, watery eyes 1
- Allergen triggers: Pollen (seasonal), mold, dust, and pet dander (perennial) 1
Age-Specific Considerations
- Adults and children ≥4 years: Approved for use 1
- Children 4–11 years: Should not use for more than 2 months per year 1
Evidence-Based Clinical Uses Beyond FDA Label
Nasal Polyposis
- Fluticasone propionate 200 mcg twice daily is effective for treating nasal polyps, reducing polyp size and improving nasal blockage symptoms over 14–26 weeks of treatment. 2
- Onset of action for polyp reduction occurs after approximately 4 weeks, with maximal benefit at 14 weeks. 2
Sinus Pain and Pressure
- Fluticasone propionate 200 mcg once daily significantly reduces sinus pain and pressure arising from allergic rhinitis compared to placebo over 14 days. 3
- This benefit occurs alongside reduction in nasal congestion, the primary driver of sinus pressure symptoms. 3
Guideline-Recommended Role in Allergic Rhinitis Management
First-Line Therapy for Moderate-to-Severe Disease
- Intranasal corticosteroids (including fluticasone propionate) are the most effective medication class for controlling all allergic rhinitis symptoms, outperforming oral antihistamines across all symptom domains. 4
- The American Academy of Otolaryngology–Head and Neck Surgery recommends intranasal corticosteroids as first-line therapy for moderate-to-severe persistent allergic rhinitis. 4
Superiority Over Alternative Agents
- Fluticasone propionate provides superior rhinitis control compared to montelukast for all nasal symptoms including congestion, rhinorrhea, sneezing, and itching. 4, 5
- Fluticasone propionate is more effective than oral antihistamines (e.g., cetirizine) for relieving nasal congestion and overall symptom burden. 4
Combination Therapy for Inadequate Response
- When symptoms remain uncontrolled after ≥2 weeks of optimal fluticasone therapy, adding an intranasal antihistamine (azelastine or olopatadine) is preferred over increasing the corticosteroid dose. 4, 6
- The fluticasone + azelastine combination achieves >40% greater overall symptom reduction than either agent alone in moderate-to-severe allergic rhinitis. 4, 6
- Adding an oral antihistamine to fluticasone does not provide additional benefit for nasal symptoms. 4, 6
Practical Administration Details
Dosing Regimens
- Standard dose: 200 mcg once daily (2 sprays per nostril of 50 mcg/spray formulation) 1
- Low-dose regimens provide comparable symptom control to high-dose regimens while halving the risk of epistaxis. 4
Onset and Duration of Action
- Onset of symptom relief occurs within 12 hours to several days; patients must use the spray daily (not as-needed) to achieve optimal benefit. 4
- Meaningful benefit is observed when medication is used on >50% of days, though daily use is recommended. 4
- As-needed use is less effective than daily scheduled administration but can provide some symptom reduction. 7
Administration Technique
- Spray laterally, away from the nasal septum, to minimize epistaxis risk and maximize drug delivery to the turbinates. 4
- In patients with severe congestion, ensure nasal patency before initiating therapy (e.g., brief course of nasal decongestant spray) to facilitate proper drug delivery. 4
Safety Profile
Common Adverse Effects
- Epistaxis is the principal local adverse effect, with risk doubling at high doses compared to standard doses. 4
- The incidence of adverse events is generally low and comparable to other intranasal corticosteroids. 2
Duration Limits
- Children 4–11 years should not use fluticasone propionate for more than 2 months per year without medical supervision. 1